
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF DESMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_1273, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF N DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_425, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF N DEALKYLPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_526, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 6PRIME BETA HYDROXY LOVASTATIN</TD><TD>BC SATISFIED ASSERTION_41, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE</TD><TD>BC SATISFIED ASSERTION_563, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 14 HYDROXYCLARITHROMYCIN</TD><TD>BC SATISFIED ASSERTION_169, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_756, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1,3 DIMETHYLURIC ACIDE1 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_755, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPO DESMETHYLVENLAFAXINED6 CONTROLS FORMATION OF O DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_427, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DEALKYLPERPHENAZINED6 CONTROLS FORMATION OF N DEALKYLPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_529, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_551, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP4 HYDROXYDEBRISOQUINED6 CONTROLS FORMATION OF 4 HYDROXYDEBRISOQUINE</TD><TD>BC SATISFIED ASSERTION_310, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP4 HYDROXYATOMOXETINED6 CONTROLS FORMATION OF 4 HYDROXYATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_709, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLROSUVASTATINC9 CONTROLS FORMATION OF N DESMETHYLROSUVASTATIN</TD><TD>BC SATISFIED ASSERTION_138, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLSERTRALINEC19 CONTROLS FORMATION OF N DESMETHYLSERTRALINE</TD><TD>BC SATISFIED ASSERTION_791, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLATOMOXETINEC19 CONTROLS FORMATION OF N DESMETHYLATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_710, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPHYDROXYBUPROPIONB6 CONTROLS FORMATION OF HYDROXYBUPROPION</TD><TD>BC SATISFIED ASSERTION_388, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1AN DEALKYLPERPHENAZINE CONTROLS FORMATION OF N DEALKYLPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_527, FURAFYLLINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1A3 METHYLXANTHINE CONTROLS FORMATION OF 3 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_757, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2</TD><TD>CYP1A3 METHYLXANTHINE CONTROLS FORMATION OF 3 METHYLXANTHINE, THEOPHYLLINE HAS METABOLITE 3 METHYLXANTHINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6</TD><TD>CYPHYDROXYBUPROPIONB6 CONTROLS FORMATION OF HYDROXYBUPROPION, BUPROPION HAS METABOLITE HYDROXYBUPROPION, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>CYPN DESMETHYLATOMOXETINEC19 CONTROLS FORMATION OF N DESMETHYLATOMOXETINE, ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>CYPN DESMETHYLSERTRALINEC19 CONTROLS FORMATION OF N DESMETHYLSERTRALINE, SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>CYPN DESMETHYLROSUVASTATINC9 CONTROLS FORMATION OF N DESMETHYLROSUVASTATIN, ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>CYP4 HYDROXYATOMOXETINED6 CONTROLS FORMATION OF 4 HYDROXYATOMOXETINE, ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE, RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>CYPO DESMETHYLVENLAFAXINED6 CONTROLS FORMATION OF O DESMETHYLVENLAFAXINE, VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP2E1 DIMETHYLURIC ACID VIA CYP2E1</TD><TD>CYP1,3 DIMETHYLURIC ACIDE1 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID, THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID, THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF 14 HYDROXYCLARITHROMYCIN, CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF N DESMETHYLVENLAFAXINE, VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, VERAPAMIL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, PROPAFENONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, NORFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, MEXILETINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, FLUVOXAMINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CIPROFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CIMETIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, AMIODARONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, ZAFIRLUKAST INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, VORICONAZOLE N OXIDE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, VORICONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, TERIFLUNOMIDE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, FLUVOXAMINE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, FLUCONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, AMIODARONE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF CLARITHROMYCIN TO 1CYP3A4 HYDROXYCLARITHROMYCIN VIA CYP3A4</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '3-METHYLXANTHINE 'THEOPHYLLINE 'CYP2E1)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '3-METHYLXANTHINE 'THEOPHYLLINE 'CYP3A4)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '1,3-DIMETHYLURIC-ACID 'THEOPHYLLINE 'CYP1A2)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         'N-DESMETHYLATOMOXETINE 'ATOMOXETINE 'CYP2D6)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '4-HYDROXYATOMOXETINE 'ATOMOXETINE 'CYP2C19)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         'O-DESMETHYLVENLAFAXINE 'VENLAFAXINE 'CYP3A4)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         'N-DESMETHYLVENLAFAXINE 'VENLAFAXINE 'CYP2D6)</TD></TR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, PROPAFENONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, NORFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, MEXILETINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, FLUVOXAMINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CIPROFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALPROATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TROLEANDOMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIFLUOPERAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIABENDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TENIPOSIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHIZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAQUINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINUPRISTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUININE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROMETHAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXYCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICARDIPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MOLINDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIFEPRISTONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDOMETHACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOROURACIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLECAINIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETHANOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DROPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DOXORUBICIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DELAVIRDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DANAZOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOTRIMAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOMIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPHENIRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORAMPHENICOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BASILIXIMAB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_249, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_289, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_44, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_25, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_78, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_288, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_763, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_787, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_711, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_597, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_217, ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, SOLE PK EFFECT OF ITRACONAZOLE ON SIMVASTATIN ALTER METABOLIC CLEARANCE, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_999, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8</TD><TD>BC SATISFIED ASSERTION_192, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_780, KETOCONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_694, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_788, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_215, SOLE PK EFFECT OF ITRACONAZOLE ON LOVASTATIN ALTER METABOLIC CLEARANCE, ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_695, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_173, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_99, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_213, SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY SIMVASTATIN ALTER METABOLIC CLEARANCE, ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_211, SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY LOVASTATIN ALTER METABOLIC CLEARANCE, ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_109, SOLE PK EFFECT OF ITRACONAZOLE ON ATORVASTATIN ALTER METABOLIC CLEARANCE, ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_293, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_100, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_291, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_133, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_292, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1001, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_395, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_7, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_776, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_17, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019, ATORVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021, BETA HYDROXY LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C9 IS 0.01, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2D6 IS 0.013, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP0.032A4 IS 0.032, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP0.004A4 IS 0.004, FLUOXETINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP1A2 IS 0.018, FLUPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP1A2, MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP2D6 IS 0.004, FLUPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008, FLUVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003, LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C19 IS 0.287, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C19, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C9 IS 0.223, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP0.153A4 IS 0.153, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP1A2 IS 0.026, PERPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP1A2, MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP2D6 IS 3.2e 4, PERPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF RISPERIDONE FOR CYP2D6 IS 0.003, RISPERIDONE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF RISPERIDONE IS 7.9e 5 AT DOSE 0.001, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1167, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_959, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1165, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1166, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1164, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1163, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_947, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1162, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_1160, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1159, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1154, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1157, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1155, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1158, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_946, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1161, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1156, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_949, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_938, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_77, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_208, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_1188, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1191, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1184, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1192, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1194, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_1193, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1187, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_1190, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1189, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1185, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A1</TD><TD>BC SATISFIED ASSERTION_1186, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_951, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_955, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1125, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1124, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1127, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1126, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_209, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_962, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_933, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_1140, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_939, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1141, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1138, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1136, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_1137, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1139, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1142, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1135, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_942, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1207, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1178, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1179, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1182, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_1181, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1177, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1180, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1183, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1304, CHLORZOXAZONE IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1303, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1302, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1305, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1306, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1208, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_957, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1196, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1197, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_1195, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1198, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_954, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_952, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1149, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_944, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1150, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1151, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1153, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1148, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1152, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1123, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1120, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_932, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1121, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_1212, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1213, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1214, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_961, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_960, TRIAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_945, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_940, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1210, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1209, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_958, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_1203, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1204, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1206, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_956, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1205, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_950, OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1216, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_963, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1215, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_40, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1128, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1129, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_934, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1171, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1173, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1174, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1172, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_1176, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1170, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1175, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1201, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_953, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1202, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1200, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1199, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_935, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1211, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_948, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1169, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1168, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1147, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_943, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1134, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_937, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1133, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1130, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1131, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1132, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_936, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_941, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1143, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1145, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1144, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1146, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_774, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_775, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_771, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_770, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_769, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_768, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_767, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_766, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_637, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_636, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_638, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_406, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_639, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_713, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_633, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_632, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_631, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_286, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_629, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_628, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1003, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_784, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_783, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_785, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1002, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_627, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_298, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_625, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_624, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_623, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_622, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_723, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_721, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_620, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1000, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_619, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_618, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1006, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_617, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_396, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_300, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_299, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_297, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_616, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_180, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_134, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_32, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_287, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_16, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_614, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_31, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_613, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_716, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_611, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_610, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_612, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_700, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_412, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_112, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_609, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_608, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_997, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_607, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_606, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_998, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF THEOPHYLLINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF WARFARIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF WARFARIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF WARFARIN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF WARFARIN</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF WARFARIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF WARFARIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF WARFARIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>GEMFIBROZIL INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSIGLITAZONE</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF VENLAFAXINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSIGLITAZONE</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF ATOMOXETINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF THIORIDAZINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LOVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY SIMVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF BETA HYDROXY LOVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF ATORVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_866, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.2</TD><TD>BC SATISFIED ASSERTION_864, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VALPROATE IS 0.5</TD><TD>BC SATISFIED ASSERTION_862, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_860, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.025</TD><TD>BC SATISFIED ASSERTION_858, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 0.25</TD><TD>BC SATISFIED ASSERTION_856, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 0.84</TD><TD>BC SATISFIED ASSERTION_854, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 1.0</TD><TD>BC SATISFIED ASSERTION_852, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.065</TD><TD>BC SATISFIED ASSERTION_850, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.0125</TD><TD>BC SATISFIED ASSERTION_848, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.02</TD><TD>BC SATISFIED ASSERTION_846, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.06</TD><TD>BC SATISFIED ASSERTION_844, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.03</TD><TD>BC SATISFIED ASSERTION_842, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 0.75</TD><TD>BC SATISFIED ASSERTION_840, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.01</TD><TD>BC SATISFIED ASSERTION_838, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.015</TD><TD>BC SATISFIED ASSERTION_836, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.02</TD><TD>BC SATISFIED ASSERTION_834, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.2</TD><TD>BC SATISFIED ASSERTION_832, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.01</TD><TD>BC SATISFIED ASSERTION_830, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_867, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.6</TD><TD>BC SATISFIED ASSERTION_865, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VALPROATE IS 4.2</TD><TD>BC SATISFIED ASSERTION_863, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_861, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.4</TD><TD>BC SATISFIED ASSERTION_859, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 3.0</TD><TD>BC SATISFIED ASSERTION_857, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 1.05</TD><TD>BC SATISFIED ASSERTION_855, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 2.0</TD><TD>BC SATISFIED ASSERTION_853, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.6</TD><TD>BC SATISFIED ASSERTION_851, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.15</TD><TD>BC SATISFIED ASSERTION_849, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.24</TD><TD>BC SATISFIED ASSERTION_847, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.12</TD><TD>BC SATISFIED ASSERTION_845, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.04</TD><TD>BC SATISFIED ASSERTION_843, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 4.0</TD><TD>BC SATISFIED ASSERTION_841, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.2</TD><TD>BC SATISFIED ASSERTION_839, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.18</TD><TD>BC SATISFIED ASSERTION_837, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.8</TD><TD>BC SATISFIED ASSERTION_835, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.8</TD><TD>BC SATISFIED ASSERTION_833, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.08</TD><TD>BC SATISFIED ASSERTION_831, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ZIPRASIDONE FOR CYP2D6 IS 0.005</TD><TD>BC SATISFIED ASSERTION_603, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2C19 IS 3.165e 4</TD><TD>BC SATISFIED ASSERTION_635, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2B6 IS 5.278e 5</TD><TD>BC SATISFIED ASSERTION_634, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIOTHIXENE FOR CYP2D6 IS 0.029</TD><TD>BC SATISFIED ASSERTION_318, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIORIDAZINE FOR CYP2D6 IS 5.699e 4</TD><TD>BC SATISFIED ASSERTION_319, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SIMVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_228, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ROSIGLITAZONE FOR CYP2C8 IS 0.002</TD><TD>BC SATISFIED ASSERTION_630, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF RISPERIDONE FOR CYP2D6 IS 0.003</TD><TD>BC SATISFIED ASSERTION_317, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PIOGLITAZONE FOR CYP2C8 IS 6.059e 4</TD><TD>BC SATISFIED ASSERTION_626, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP2D6 IS 3.2e 4</TD><TD>BC SATISFIED ASSERTION_256, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP1A2 IS 0.026</TD><TD>BC SATISFIED ASSERTION_255, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PALIPERIDONE FOR CYP2D6 IS 0.007</TD><TD>BC SATISFIED ASSERTION_601, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP0.153A4 IS 0.153</TD><TD>BC SATISFIED ASSERTION_1274, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C9 IS 0.223</TD><TD>BC SATISFIED ASSERTION_1276, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C19 IS 0.287</TD><TD>BC SATISFIED ASSERTION_1278, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NORFLUOXETINE FOR CYP4.252e 4A4 IS 4.252e 4</TD><TD>BC SATISFIED ASSERTION_1282, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF MONTELUKAST FOR CYP2C8 IS 6.448e 4</TD><TD>BC SATISFIED ASSERTION_621, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_221, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A4 IS 1.966e 6</TD><TD>BC SATISFIED ASSERTION_1286, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ITRACONAZOLE FOR CYP1.94e 4A4 IS 1.94e 4</TD><TD>BC SATISFIED ASSERTION_1285, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF HALOPERIDOL FOR CYP2D6 IS 0.003</TD><TD>BC SATISFIED ASSERTION_316, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVOXAMINE FOR CYP1A2 IS 2.072e 5</TD><TD>BC SATISFIED ASSERTION_566, THEOPHYLLINE IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008</TD><TD>BC SATISFIED ASSERTION_223, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP2D6 IS 0.004</TD><TD>BC SATISFIED ASSERTION_253, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP1A2 IS 0.018</TD><TD>BC SATISFIED ASSERTION_254, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP0.004A4 IS 0.004</TD><TD>BC SATISFIED ASSERTION_1283, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP3.89e 4A4 IS 3.89e 4</TD><TD>BC SATISFIED ASSERTION_1284, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ERYTHROMYCIN FOR CYP0.006A4 IS 0.006</TD><TD>BC SATISFIED ASSERTION_224, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF DILTIAZEM FOR CYP2.2e 4A4 IS 2.2e 4</TD><TD>BC SATISFIED ASSERTION_220, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP0.032A4 IS 0.032</TD><TD>BC SATISFIED ASSERTION_1275, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2D6 IS 0.013</TD><TD>BC SATISFIED ASSERTION_315, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C9 IS 0.01</TD><TD>BC SATISFIED ASSERTION_1277, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C19 IS 0.023</TD><TD>BC SATISFIED ASSERTION_1279, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOPIDOGREL FOR CYP2B6 IS 1.609e 4</TD><TD>BC SATISFIED ASSERTION_615, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLARITHROMYCIN FOR CYP0.00168A4 IS 0.00168</TD><TD>BC SATISFIED ASSERTION_226, TESTOSTERONE IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY SIMVASTATIN FOR CYP2C8 IS 0.018</TD><TD>BC SATISFIED ASSERTION_227, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021</TD><TD>BC SATISFIED ASSERTION_240, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019</TD><TD>BC SATISFIED ASSERTION_222, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF 9 HYDROXYRISPERIDONE FOR CYP2D6 IS 0.007</TD><TD>BC SATISFIED ASSERTION_602, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS SUBSTRATE OF CYP2B6</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS SUBSTRATE OF CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP2E1</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP2E1 DIMETHYLURIC ACID VIA CYP2E1, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS SUBSTRATE OF CYP2C8</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_879, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_878, ITRACONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_422, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_877, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_772, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_759, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_761, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_760, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_593, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_405, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_385, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_290, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_746, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_745, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_748, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_747, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_8, ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_789, CYP2C19 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1281, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_570, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_605, TROLEANDOMYCIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_779, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_737, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_736, CLARITHROMYCIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_735, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_398, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_505, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_507, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_506, FURAFYLLINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_553, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_734, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_733, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_556, FLUOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1280, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_724, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_514, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_513, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_511, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_512, ALPHA NAPHTHOFLAVONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_153, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_688, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_687, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_689, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1007, KETOCONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1008, FLUOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_562, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_394, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_175, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_174, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_176, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_383, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_681, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_490, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_494, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_401, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_306, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_308, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_96, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_266, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_416, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_415, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_414, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_168, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_409, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_697, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_698, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_699, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_701, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_20, ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_148, KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_115, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_281, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_282, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_23, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_497, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_498, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_491, KETOCONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_495, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_380, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_97, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM PERMANENTLY DEACTIVATES CATALYTIC FUNCTION OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_13, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THREOHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE 5 SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>REDUCED HALOPERIDOL IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORPROPOXYPHENE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLUOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXY HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESMETHYLCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESGLYMIDODRINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA NAPHTHOFLAVONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S ZOPICLONE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S METHYL DIHYDROZIPRASIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S N DESMETHYLZOPICLONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>O DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLTAMOXIFEN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLSERTRALINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYL_ERYTHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>M CHLOROPHENYLPIPERAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>9 HYDROXYRISPERIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYPERPHENAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY N DESALKYL QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXYMETHYL SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6BETA HYDROXYTESTOSTERONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTRIAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTAMOXIFIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYDEBRISOQUINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3ALPHA HYDROXYPRAVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1PRIME HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>14 HYDROXYCLARITHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>10 N GLUCURONIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1,3 DIMETHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS ANCESTOR OF 3 METHYLXANTHINE</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS ANCESTOR OF HYDROXYBUPROPION</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS ANCESTOR OF N DESMETHYLATOMOXETINE</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS ANCESTOR OF N DESMETHYLSERTRALINE</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS ANCESTOR OF N DESMETHYLROSUVASTATIN</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS ANCESTOR OF 4 HYDROXYATOMOXETINE</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS ANCESTOR OF 9 HYDROXYRISPERIDONE</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS ANCESTOR OF O DESMETHYLVENLAFAXINE</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS ANCESTOR OF 1,3 DIMETHYLURIC ACID</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS ANCESTOR OF 14 HYDROXYCLARITHROMYCIN</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS ANCESTOR OF N DESMETHYLVENLAFAXINE</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, </TD></TR><BR>
<TR><TD>(BC-SATISFIED 'ASSERTION_86)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_85)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_84)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_76)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_73)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_669)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_66)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_65)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_6)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_42)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_33)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_320)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_294)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_27)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_24)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_21)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_204)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_203)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_202)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_200)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_199)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_198)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_196)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_194)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_179)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_159)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_158)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_157)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_156)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_154)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_110)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_11)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_216)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_212)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_210)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_108)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_391)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_686)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_764)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_407)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_782)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_781)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_390)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_749)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_744)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_2)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_136)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_516)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_778)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_738)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_397)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_103)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_311)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_552)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_546)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_720)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_690)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_30)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_714)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_389)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_393)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_421)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_132)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_400)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_55)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_728)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_417)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_411)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_717)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_702)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_111)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_705)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1005)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_283)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_71)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_548)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_133)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_763)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_787)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_7)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_711)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_597)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_395)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_217)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_999)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_192)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_780)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_694)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_788)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_17)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_215)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_695)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_173)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_291)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_292)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_99)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1001)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_213)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_211)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_109)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_293)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_776)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_100)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_139)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_550)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_53)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_141)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_68)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_866)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_864)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_862)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_860)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_858)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_856)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_854)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_852)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_850)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_848)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_846)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_844)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_842)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_840)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_838)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_836)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_834)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_832)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_830)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_867)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_865)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_863)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_861)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_859)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_857)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_855)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_853)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_851)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_849)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_847)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_845)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_843)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_841)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_839)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_837)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_835)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_833)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_831)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_880)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_582)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_773)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_758)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_585)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_590)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_598)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_142)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_544)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_777)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_312)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_732)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_545)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_692)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_144)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_693)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_83)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_596)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_170)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_588)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_130)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_499)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_599)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_47)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_418)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_39)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_508)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_703)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_413)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_149)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_128)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1004)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_583)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_102)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_503)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_502)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_504)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_501)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_586)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_314)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_58)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_603)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_634)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_318)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_319)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_228)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_630)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_317)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_626)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_256)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_255)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_601)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1274)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1276)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1278)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1282)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_621)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_221)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1286)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_316)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_566)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_223)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_253)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_254)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1283)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1284)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_224)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_220)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1275)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_315)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1277)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1279)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_615)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_226)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_227)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_240)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_222)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_685)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_762)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_591)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_135)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_515)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_739)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_731)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_547)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_725)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_510)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_727)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_150)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_691)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_715)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_392)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_171)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_587)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_399)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_29)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_14)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_410)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_565)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_704)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_284)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_5)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_13)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_879)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_878)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_422)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_877)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_772)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_759)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_761)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_760)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_593)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_405)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_385)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_746)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_745)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_748)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_747)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_8)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_789)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1281)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_570)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_605)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_779)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_737)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_736)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_735)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_398)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_505)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_507)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_506)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_553)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_734)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_733)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_556)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1280)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_724)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_513)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_511)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_512)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_688)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_687)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_689)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1007)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1008)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_562)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_394)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_175)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_174)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_383)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_681)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_490)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_494)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_401)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_306)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_308)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_96)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_266)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_415)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_414)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_168)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_697)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_698)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_699)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_701)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_20)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_148)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_117)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_115)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_281)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_282)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_23)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_497)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_498)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_491)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_449)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_380)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_97)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_924)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_231)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1075)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1072)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1073)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1074)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1068)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1070)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1071)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1069)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_928)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_904)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_234)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_230)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_233)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1056)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1061)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1066)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1065)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1064)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1063)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1062)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_912)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1060)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_235)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_80)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_163)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_36)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_52)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_162)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_101)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_48)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_453)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_54)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_183)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_664)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_74)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_12)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_250)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_309)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_665)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1270)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_600)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_663)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_454)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_577)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_249)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_44)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_25)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_78)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_288)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_9)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_569)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_567)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_26)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_38)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_59)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_22)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_774)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_775)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_771)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_770)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_769)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_768)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_767)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_766)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_637)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_636)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_638)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_406)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_639)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_713)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_633)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_632)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_286)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_629)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1003)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_784)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_783)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_785)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1002)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_627)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_625)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_623)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_723)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_721)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_620)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_4)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1000)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_618)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1006)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_617)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_300)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_299)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_297)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_180)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_134)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_32)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_16)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_614)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_31)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_613)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_716)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_611)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_610)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_612)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_700)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_412)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_112)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_609)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_997)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_607)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_606)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_998)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_366)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_364)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_365)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_367)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_765)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_429)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_426)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_384)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_584)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_518)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_517)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_753)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_751)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_750)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_752)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_740)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_741)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_3)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_381)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_137)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_549)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_520)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_379)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_521)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_519)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_729)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_193)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_561)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_722)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_726)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_145)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_712)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_594)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_382)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_683)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_684)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_369)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_368)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_105)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_106)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_522)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_524)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_523)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_18)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_371)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_370)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_719)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_718)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1250)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_67)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_56)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_79)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_114)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_113)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_708)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_707)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_265)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_70)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_35)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_754)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_248)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_247)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_246)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_245)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_244)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_243)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_242)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_241)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1167)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_959)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1165)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1166)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1163)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_947)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1162)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1160)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1159)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1154)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1157)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1158)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_946)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1161)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1156)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_949)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_938)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_77)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1188)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1191)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1184)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1192)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1194)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1193)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1187)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1190)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1189)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1185)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_951)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_955)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1125)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1124)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1127)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_209)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_962)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_933)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1140)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_939)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1141)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1138)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1136)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1137)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1139)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1142)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1135)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_942)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1207)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1178)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1179)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1182)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1181)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1177)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1180)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1183)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1304)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1303)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1302)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1305)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1306)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_957)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1196)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1195)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1198)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_954)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_952)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1149)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_944)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1150)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1148)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1123)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1120)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_932)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1121)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1212)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1213)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_961)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_960)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_945)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_940)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1210)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1209)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_958)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1203)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1204)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_956)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_950)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1216)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_963)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1215)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_40)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1128)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_934)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1171)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1173)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1174)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1170)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1175)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_953)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1202)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1200)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1199)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_935)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1211)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_948)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1169)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1168)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1147)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_943)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1134)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_937)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1133)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1130)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1132)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_936)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_941)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1143)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1145)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1144)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1146)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1273)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_425)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_743)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_526)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_41)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_563)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_169)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_756)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_755)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_427)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_529)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_551)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_310)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_709)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_138)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_791)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_710)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_527)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_757)</TD></TR>
<TR><TD>Z</TD><TD>TROLEANDOMYCIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_80, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_163, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_52, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA NAPHTHOFLAVONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_101, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_36, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_164, </TD></TR><BR>
<TR><TD>Z</TD><TD>FURAFYLLINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_162, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_589, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_12, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_309, </TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_54, </TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_577, </TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_664, </TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_663, </TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_665, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_183, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1270, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_74, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_600, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_48, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_252, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_250, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_453, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_454, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_251, </TD></TR><BR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         '9-HYDROXYRISPERIDONE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOPIDOGREL
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUCONAZOLE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUOXETINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'FLUPHENAZINE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'FLUPHENAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVOXAMINE
         'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'HALOPERIDOL
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ITRACONAZOLE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'MONTELUKAST
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'NORFLUOXETINE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PALIPERIDONE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PERPHENAZINE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PERPHENAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PIOGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'RISPERIDONE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ROSIGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'THIORIDAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'THIOTHIXENE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ZIPRASIDONE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'SIMVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'LOVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ERYTHROMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'CLARITHROMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-SIMVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-LOVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ATORVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE ZIPRASIDONE SULPHOXIDE</TD><TD>BC SATISFIED ASSERTION_366, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE BENZISOTHIAZOLE SULPHOXIDE</TD><TD>BC SATISFIED ASSERTION_364, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE BENZISOTHIAZOLE SULPHONE</TD><TD>BC SATISFIED ASSERTION_365, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE S METHYL DIHYDROZIPRASIDONE</TD><TD>BC SATISFIED ASSERTION_367, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE HAS METABOLITE VORICONAZOLE N OXIDE</TD><TD>BC SATISFIED ASSERTION_765, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_429, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_426, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE HAS METABOLITE M CHLOROPHENYLPIPERAZINE</TD><TD>BC SATISFIED ASSERTION_384, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE THIORIDAZINE 5 SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_584, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE SULFORIDAZINE</TD><TD>BC SATISFIED ASSERTION_518, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE MESORIDAZINE</TD><TD>BC SATISFIED ASSERTION_517, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE CAFFEINE</TD><TD>BC SATISFIED ASSERTION_753, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 3 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_751, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_750, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_752, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN HAS METABOLITE N DESMETHYLTAMOXIFEN</TD><TD>BC SATISFIED ASSERTION_740, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN HAS METABOLITE 4 HYDROXYTAMOXIFIN</TD><TD>BC SATISFIED ASSERTION_741, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN HAS METABOLITE BETA HYDROXY SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_3, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE</TD><TD>BC SATISFIED ASSERTION_381, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN</TD><TD>BC SATISFIED ASSERTION_137, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_549, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE QUETIAPINE SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_520, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE N DESALKYLQUETIAPINE</TD><TD>BC SATISFIED ASSERTION_379, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_521, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY N DESALKYL QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_519, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE HAS METABOLITE NORPROPOXYPHENE</TD><TD>BC SATISFIED ASSERTION_729, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN HAS METABOLITE 3ALPHA HYDROXYPRAVASTATIN</TD><TD>BC SATISFIED ASSERTION_193, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE HAS METABOLITE 7 HYDROXYPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_313, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE HAS METABOLITE 10 N GLUCURONIDE</TD><TD>BC SATISFIED ASSERTION_561, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL HAS METABOLITE MODAFINIL SULFONE</TD><TD>BC SATISFIED ASSERTION_722, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE HAS METABOLITE DESGLYMIDODRINE</TD><TD>BC SATISFIED ASSERTION_726, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN HAS METABOLITE BETA HYDROXY LOVASTATIN</TD><TD>BC SATISFIED ASSERTION_145, </TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE HAS METABOLITE TERIFLUNOMIDE</TD><TD>BC SATISFIED ASSERTION_712, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL HAS METABOLITE REDUCED HALOPERIDOL</TD><TD>BC SATISFIED ASSERTION_594, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE HAS METABOLITE NORFLUOXETINE</TD><TD>BC SATISFIED ASSERTION_382, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE HAS METABOLITE S ZOPICLONE N OXIDE</TD><TD>BC SATISFIED ASSERTION_683, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE HAS METABOLITE S N DESMETHYLZOPICLONE</TD><TD>BC SATISFIED ASSERTION_684, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM HAS METABOLITE S DIDEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_369, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM HAS METABOLITE S DEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_368, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE DESACETYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_105, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_107, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDESACETYL DILTIAZEM</TD><TD>BC SATISFIED ASSERTION_106, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE DESMETHYLCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_522, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE CLOZAPINE N OXIDE</TD><TD>BC SATISFIED ASSERTION_524, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE 7 HYDROXYCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_523, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN</TD><TD>BC SATISFIED ASSERTION_18, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM HAS METABOLITE DIDEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_371, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM HAS METABOLITE DEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_370, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET HAS METABOLITE HYDROXY HYDROCINNAMIC ACID</TD><TD>BC SATISFIED ASSERTION_719, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET HAS METABOLITE HYDROCINNAMIC ACID</TD><TD>BC SATISFIED ASSERTION_718, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE THREOHYDROBUPROPION</TD><TD>BC SATISFIED ASSERTION_1252, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION</TD><TD>BC SATISFIED ASSERTION_1251, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE ERYTHROHYDROBUPROPION</TD><TD>BC SATISFIED ASSERTION_1250, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME HYDROXYMETHYL SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_67, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME HYDROXY SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_56, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME EXOMETHYLENE SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_79, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_114, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_113, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_708, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_707, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE HAS METABOLITE DEHYDRO ARIPIPRAZOLE</TD><TD>BC SATISFIED ASSERTION_265, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM HAS METABOLITE ALPHA HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_70, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM HAS METABOLITE 4 HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_35, </TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE HAS METABOLITE 1 METHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_754, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN IN VIVO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_569, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_567, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_571, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_26, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2D6 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_38, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2C9 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_59, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2C19 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_22, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_924, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_231, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1295, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1075, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1072, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1073, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1074, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1068, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1070, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1071, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A1</TD><TD>BC SATISFIED ASSERTION_1069, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_928, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_904, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_234, QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_230, SULPHAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_233, FURAFYLLINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1056, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1061, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1066, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1065, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1064, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1063, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1062, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_912, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A1</TD><TD>BC SATISFIED ASSERTION_1060, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_235, ALPHA NAPHTHOFLAVONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ZALEPLON IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_685, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF VORICONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_762, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF TRAZODONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_591, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_135, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RISPERIDONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_515, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RABEPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_739, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PANTOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_731, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PALIPERIDONE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_547, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF NICARDIPINE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_725, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIRTAZAPINE IS MEDIUM HIGH</TD><TD>BC SATISFIED ASSERTION_510, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIDODRINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_727, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LOVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_150, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LANSOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_691, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF INDOMETHACIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_715, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVOXAMINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_392, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVASTATIN IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_171, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUPHENAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_587, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUCONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_131, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ESCITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_399, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF DILTIAZEM IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_29, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_14, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_410, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CHLORPROMAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_565, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATORVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_129, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATOMOXETINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_704, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ARIPIPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_284, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ALPRAZOLAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_5, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZOLPIDEM IS 1.06e 4 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_880, ASSUMED EFFECTIVE DOSE OF ZOLPIDEM IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZIPRASIDONE IS 1.0.1294e 4 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_582, ASSUMED EFFECTIVE DOSE OF ZIPRASIDONE IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VORICONAZOLE IS 4.66e 4 AT DOSE 0.6</TD><TD>BC SATISFIED ASSERTION_758, ASSUMED EFFECTIVE DOSE OF VORICONAZOLE IS 0.6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VENLAFAXINE IS 0.45.90.45e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_585, ASSUMED EFFECTIVE DOSE OF VENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF TRAZODONE IS 0.002 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_590, ASSUMED EFFECTIVE DOSE OF TRAZODONE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF THREOHYDROBUPROPION IS 5.098e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_598, ASSUMED EFFECTIVE DOSE OF THREOHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ROSUVASTATIN IS 1.88e 5 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_142, ASSUMED EFFECTIVE DOSE OF ROSUVASTATIN IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RISPERIDONE IS 7.9e 5 AT DOSE 0.001</TD><TD>BC SATISFIED ASSERTION_544, ASSUMED EFFECTIVE DOSE OF RISPERIDONE IS 0.001, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RANOLAZINE IS 2.6e 4 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_777, ASSUMED EFFECTIVE DOSE OF RANOLAZINE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_312, ASSUMED EFFECTIVE DOSE OF PERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PANTOPRAZOLE IS 2.5e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_732, ASSUMED EFFECTIVE DOSE OF PANTOPRAZOLE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125</TD><TD>BC SATISFIED ASSERTION_545, ASSUMED EFFECTIVE DOSE OF OLANZAPINE IS 0.0125, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF METRONIDAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_692, ASSUMED EFFECTIVE DOSE OF METRONIDAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_144, ASSUMED EFFECTIVE DOSE OF LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LANSOPRAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_693, ASSUMED EFFECTIVE DOSE OF LANSOPRAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_83, ASSUMED EFFECTIVE DOSE OF KETOCONAZOLE IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF HYDROXYBUPROPION IS 0.001 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_596, ASSUMED EFFECTIVE DOSE OF HYDROXYBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_170, ASSUMED EFFECTIVE DOSE OF FLUVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012</TD><TD>BC SATISFIED ASSERTION_588, ASSUMED EFFECTIVE DOSE OF FLUPHENAZINE IS 0.012, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_420, ASSUMED EFFECTIVE DOSE OF FLUOXETINE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4</TD><TD>BC SATISFIED ASSERTION_130, ASSUMED EFFECTIVE DOSE OF FLUCONAZOLE IS 0.4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ESCITALOPRAM IS 5.002e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_499, ASSUMED EFFECTIVE DOSE OF ESCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ERYTHROHYDROBUPROPION IS 1.457e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_599, ASSUMED EFFECTIVE DOSE OF ERYTHROHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF DILTIAZEM IS 6.067e 5 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_47, ASSUMED EFFECTIVE DOSE OF DILTIAZEM IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_418, ASSUMED EFFECTIVE DOSE OF CLOZAPINE IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLARITHROMYCIN IS 0.00251 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_39, ASSUMED EFFECTIVE DOSE OF CLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CHLORPROMAZINE IS 0.1.79e 5 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_508, ASSUMED EFFECTIVE DOSE OF CHLORPROMAZINE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CELECOXIB IS 7.05e 5 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_703, ASSUMED EFFECTIVE DOSE OF CELECOXIB IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BUPROPION IS 1.44e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_413, ASSUMED EFFECTIVE DOSE OF BUPROPION IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_149, ASSUMED EFFECTIVE DOSE OF BETA HYDROXY LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08</TD><TD>BC SATISFIED ASSERTION_128, ASSUMED EFFECTIVE DOSE OF ATORVASTATIN IS 0.08, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ASENAPINE IS 4.0e 6 AT DOSE 0.005</TD><TD>BC SATISFIED ASSERTION_1004, ASSUMED EFFECTIVE DOSE OF ASENAPINE IS 0.005, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ARIPIPRAZOLE IS 4.52e 4 AT DOSE 0.03</TD><TD>BC SATISFIED ASSERTION_583, ASSUMED EFFECTIVE DOSE OF ARIPIPRAZOLE IS 0.03, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ALPRAZOLAM IS 0.003.7e 5 AT DOSE 0.003</TD><TD>BC SATISFIED ASSERTION_102, ASSUMED EFFECTIVE DOSE OF ALPRAZOLAM IS 0.003, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DIDEMETHYLCITALOPRAM IS 1.897e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_503, ASSUMED EFFECTIVE DOSE OF S DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DEMETHYLCITALOPRAM IS 1.40.047e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_502, ASSUMED EFFECTIVE DOSE OF S DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DIDEMETHYLCITALOPRAM IS 0.04.971e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_504, ASSUMED EFFECTIVE DOSE OF R DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DEMETHYLCITALOPRAM IS 1.946e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_501, ASSUMED EFFECTIVE DOSE OF R DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF O DESMETHYLVENLAFAXINE IS 6.86e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_586, ASSUMED EFFECTIVE DOSE OF O DESMETHYLVENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 7 HYDROXYPERPHENAZINE IS 5.09e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_314, ASSUMED EFFECTIVE DOSE OF 7 HYDROXYPERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 14 HYDROXYCLARITHROMYCIN IS 8.8e 4 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_58, ASSUMED EFFECTIVE DOSE OF 14 HYDROXYCLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZOLPIDEM '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZIPRASIDONE '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VORICONAZOLE '0.6)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'TRAZODONE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'THREOHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ROSUVASTATIN '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RISPERIDONE '0.001)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RANOLAZINE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PANTOPRAZOLE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'OLANZAPINE '0.0125)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'METRONIDAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LANSOPRAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'KETOCONAZOLE '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'HYDROXYBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUPHENAZINE '0.012)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUOXETINE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUCONAZOLE '0.4)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ESCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ERYTHROHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'DILTIAZEM '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLOZAPINE '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CHLORPROMAZINE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CELECOXIB '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BUPROPION '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BETA-HYDROXY-LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ATORVASTATIN '0.08)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ASENAPINE '0.005)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ARIPIPRAZOLE '0.03)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ALPRAZOLAM '0.003)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'O-DESMETHYLVENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '7-HYDROXYPERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '14-HYDROXYCLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_141, </TD></TR><BR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_68, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_139, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF RISPERIDONE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_550, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ALPRAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_53, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON SIMVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_216, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON LOVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_214, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY SIMVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_212, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY LOVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_210, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON ATORVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_108, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MIDAZOLAM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF S WARFARIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TRIAZOLAM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THEOPHYLLINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF THEOPHYLLINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CAFFEINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESIPRAMINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF WARFARIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DEXTROMETHORPHAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF N DEMETHYLDESACETYL DILTIAZEM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATOMOXETINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATOMOXETINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATORVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATORVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF BETA HYDROXY LOVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF BETA HYDROXY SIMVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BETA HYDROXY SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESACETYLDILTIAZEM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LANSOPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LOVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LOVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF OMEPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PANTOPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RANOLAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSIGLITAZONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SILDENAFIL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIMVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THIORIDAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF THIORIDAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOLBUTAMIDE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VENLAFAXINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VENLAFAXINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VORICONAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ZIPRASIDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_391, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ZALEPLON IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_686, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VORICONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_764, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VENLAFAXINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_407, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VALPROATE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_782, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOPIRAMATE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_781, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THREOHYDROBUPROPION IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_390, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THEOPHYLLINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_749, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TAMOXIFEN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_744, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIMVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS BILIARY_EXCRETION</TD><TD>BC SATISFIED ASSERTION_136, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RISPERIDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_516, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RANOLAZINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_778, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RABEPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_738, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUETIAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_397, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PRAVASTATIN IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_103, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PERPHENAZINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_311, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PAROXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_552, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PALIPERIDONE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_546, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MOLINDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_285, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MODAFINIL IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_720, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LOVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_152, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LANSOPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_690, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF KETOCONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_30, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF INDOMETHACIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_714, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF HYDROXYBUPROPION IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_389, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVOXAMINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_393, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_172, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_421, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUCONAZOLE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_132, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ESCITALOPRAM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_400, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DULOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_307, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DILTIAZEM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_55, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESGLYMIDODRINE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_728, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CLOZAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_417, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CITALOPRAM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_411, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CINACALCET IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_717, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CELECOXIB IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_702, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATORVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_111, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATOMOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_705, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ASENAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1005, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ARIPIPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_283, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALPRAZOLAM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_71, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF 9 HYDROXYRISPERIDONE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_548, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLARITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DILTIAZEM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ERYTHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>FLUVOXAMINE INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>FLUVOXAMINE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>GEMFIBROZIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>GEMFIBROZIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ITRACONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>KETOCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MEXILETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MEXILETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MEXILETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MEXILETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL SULFONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL SULFONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TRIMETHOPRIM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TRIMETHOPRIM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ALPRAZOLAM IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, RANOLAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIMVASTATIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, RISPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF REDUCED HALOPERIDOL VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, REDUCED HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, RABEPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, PERPHENAZINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, NEFAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ILOPERIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF HALOPERIDOL VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, HALOPERIDOL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ESCITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CLARITHROMYCIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY SIMVASTATIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY SIMVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BETA HYDROXY LOVASTATIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, BETA HYDROXY LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, R CITALOPRAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, PERPHENAZINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, ESCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, S DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R DEMETHYLCITALOPRAM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, R DEMETHYLCITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF R CITALOPRAM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, R CITALOPRAM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>